CHM Rab escort protein

Gene Context Sentence

Table 2. Analysis of context sentence of CHM gene in 5 abstracts.

PMID Gene Context Sentence
32233641 Traditional Chinese herbal medicines (CHM) have unique roles in the treatment of viral infections. […] In this article we analyzed the effectiveness and possible molecular mechanisms of CHM formulas for the prevention of COVID-19. […] The active ingredients and action targets of CHM formulas were obtained from the TCMSP database. […] The action mechanisms of these genes were predicted using a Gene Ontology (GO)-based functional enrichment and annotation tool and the Kyoto Encyclopedia of Genes and Genomes (KEGG). […] CHM formulas played a positive role in preventing COVID-19 and warrant further application. […] Our research provides new evidence to support the possible value of CHM formulas for the prevention of COVID-19.
32349517 In addition, we also summarized preclinical rationale for anti-coronavirus activity by TCM in terms of virion assembly and release, as well as viral entry and replication, which could be a useful contribution for figuring out effective Chinese herbal medicine (CHM) for coronavirus, including ingredients from single monomeric compounds, Chinese herbs, Chinese herb extracts and Chinese herb formulas, or potential targets for medicine. […] We would like to see these relevant studies, ranging from basic researches to clinical application, could provide some idea on effects of CHM to combat COVID-19 or other coronaviruses, and also offer new thinking for the exploration of therapeutic strategies under the guidance of TCM.
32481380 Traditional Chinese medicines (CHM) is widely used in treating COVID-19 in China. […] Our study aims to systematically present the clinical evidence of CHM in the treatment of COVID-19, which will be of guiding significance for further research and clinical practice.
32574340 Chinese herbal medicine (CHM) was also included as part of the treatment plans at various stages of COVID-19. Methods: We conducted a pilot randomized, controlled trial in patients with severe COVID-19 in Wuhan, China. […] Eligible adult patients were randomly assigned in a 2:1 ratio to receive either CHM plus standard care or standard care alone for 7 days. […] The primary outcome was the change in the disease severity category of COVID-19 after treatment. Results: Between Jan 31, 2020, and Feb 19, 2020, 42 out of 100 screened patients were included in the trial: 28 in the CHM plus standard care group and 14 in the standard care alone group. […] For the primary outcome, one patient from each group died during treatment; the odds of a shift toward death was lower in the CHM plus group than in the standard care alone group (common OR 0.59, 95% CI 0.148-2.352, P = 0.454). […] Three (two from the CHM plus group and one from the standard care alone group) patients progressed from severe to critical illness. […] 7.14% (1/28) of the patients treated with CHM plus standard care vs. standard care alone. Conclusions: For the first time, the G-CHAMPS trial provided valuable information for the national guideline-based CHM treatment of hospitalized patients with severe COVID-19. […] The effects of CHM in COVID-19 may be clinically important and warrant further consideration and studies. Clinical Trial Registration:
32589449 The use of Chinese herbal medicines (CHMs) might have a role in the treatment and symptomatic management of patients with COVID-19. […] It was aimed at providing an overview of the available evidence and ongoing trials concerning the effects of CHMs for the treatment of COVID-19. Methods: This is a narrative review of relevant studies. […] Four guidelines provided recommendations on the use of CHMs; these guidelines were developed in China and South Korea and were based on the consensus of experts exclusively. […] The remaining 21 guidelines provided no guidance on CHMs. […] No finished RCTs of CHMs for the treatment of patients with COVID-19 was found. […] According to the evidence evaluated in this review, a Cochrane review of CHMs for severe acute respiratory syndrome and five uncontrolled observational studies of the effects of CHMs in patients with COVID-19, the effects of CHMs for COVID-19 are unknown. […] A total of 52 ongoing clinical trials of CHM interventions for the treatment of COVID-19 were found. […] Forty-seven trials (90%) will have a sample size <400 participants. Conclusions: To the authors’ knowledge, only the Chinese and the South Korean guidelines recommend CHMs as a treatment option for patients with COVID-19. […] Clinical guidelines or health authorities from other countries do not provide advice on CHMs. […] Due to the absence of RCT, there is currently no reliable evidence on the effects of any specific CHM intervention for the treatment of patients with COVID-19.